KPTI - Karyopharm Therapeutics

-

$undefined

N/A

(N/A)

Karyopharm Therapeutics NasdaqGS:KPTI Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Location: 85 Wells Avenue, Newton, MA, 02459-3298, United States | Website: https://www.karyopharm.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

236.2M

Cash

69.94M

Avg Qtr Burn

-30.69M

Short % of Float

25.11%

Insider Ownership

6.39%

Institutional Own.

42.88%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XPOVIO (Selinexor) (XPO1 inhibitor) Details
Multiple myeloma, Diffuse large B cell lymphoma, Cancer

Approved

Quarterly sales

XPOVIO (Selinexor) (XPO1 inhibitor) Details
Cancer, Endometrial cancer

Big Mover™

Susp. Mover™

Phase 3

Data readout

XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib Details
Myelofibrosis

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 3

Data readout

XPOVIO (Selinexor) Details
Myelofibrosis, Primary immune thrombocytopenia

Phase 2

Data readout

Phase 2

Data readout

Eltanexor Details
Myelodysplastic syndrome, Blood cancer

Phase 2

Update

Phase 2

Update

Phase 1

Update

Failed

Discontinued

Failed

Discontinued

XPOVIO (Selinexor) (XPO1 inhibitor) Details
Rare diseases, Liposarcoma, Cancer

Failed

Discontinued

Failed

Discontinued